ArticleOncogene1999
Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments.
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 86 citations in OpenAlex.
- Reliable repurposing of the antibody interactome inside the cell.Nature communications · 2026Article
- Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma.Journal of blood medicine · 2024Article
- Antibody-Based Approaches to Target Pancreatic Tumours.Antibodies (Basel, Switzerland) · 2022Review
- Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53Discover oncology · 2021Article
- Review
- Single domain intrabodies against WASP inhibit TCR-induced immune responses in transgenic mice T cells.Scientific reports · 2013Article
- Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain.The Journal of biological chemistry · 2010Article
- Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation.BMC biotechnology · 2010Article
- TP53 mutations in human cancers: origins, consequences, and clinical use.Cold Spring Harbor perspectives in biology · 2010Review
- Bicistronic DNA display for in vitro selection of Fab fragments.Nucleic acids research · 2009Article
- Intrabody and Parkinson's disease.Biochimica et biophysica acta · 2009Review
- Review
- Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2007Article
- [Monoclonal antibodies: technology around the clock for new therapeutic hopes].Comptes rendus biologies · 2006Review
- CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity.Journal of negative results in biomedicine · 2004Article
- Molecular approaches to sarcoma therapy.Sarcoma · 2002Article
- Article
- Strategies for manipulating the p53 pathway in the treatment of human cancer.The Biochemical journal · 2000Review
- Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways.Oncogene · 2000Article
- Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment.Oncogene · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report here the production and the properties of single chain Fv fragments (scFvs) derived from the anti-p53 monoclonal antibodies PAb421 and 11D3. 11D3 is a newly generated monoclonal antibody which exhibits properties very comparable to those of PAb421. The scFvs PAb421 and 11D3 are able to stably associate with p53 and to restore the DNA binding activity of some p53 mutants in vitro. When expressed in p53 -/-human tumour cells, the scFv421 is essentially localized in the cytoplasm in the absence of p53, and in the nucleus when exogenous p53 is present. Thus, p53 is also able to stably associate with an anti-p53 scFv in cells. Cotransfection of p53 -/- human tumour cells with expression vectors encoding the His273 p53 mutant and either scFv leads to restoration of the p53 mutant deficient transcriptional activity. These data demonstrate that, in human tumour cells, these scFvs are able to restore a function essential for the tumour suppressor activity of p53 and may represent a novel class of molecules for p53-based cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.